Evidence map›Paper›PMID 39539704›Full record

ArticleFrontiers in microbiology2024

Subtractive genomics and comparative metabolic pathways profiling revealed novel drug targets in

Liesong Chen, Zhuojia Zhang, Qilin Zeng, Wei Wang, Hui Zhou, Yimou Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. [Advances in clinical pharmacotherapy for neonatalZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Liesong ChenInstitute of Pathogenic Biology, School of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang, China.
Zhuojia ZhangInstitute of Pathogenic Biology, School of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang, China.
Qilin ZengInstitute of Pathogenic Biology, School of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang, China.
Wei WangSpecial Inspection Department, Hengyang Traditional Chinese Medicine Hospital, Hengyang, China.
Hui ZhouCenter for Medical Test and Pathology, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, China.
Yimou WuInstitute of Pathogenic Biology, School of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: We employed a subtractive genomics approach combined with comparative metabolic pathway analysis to identify novel drug targets against Results: Our subtractive genomics analysis successfully narrowed down the proteomes of the 13 Ureaplasma strains to two target proteins, B5ZC96 and B5ZAH8. After further in-depth analyses, the results suggested that these two proteins may serve as novel therapeutic targets against Discussion: The identification of B5ZC96 and B5ZAH8 as novel drug targets marked a significant advancement toward developing new therapeutic strategies against

Indexed as

drug targetsmetabolic pathwayssubtractive genomicsUreaplasma urealyticumvirtual highthroughput screening

Identifiers

PMID39539704
PMCPMC11557531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.